Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
63.6M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
69.3M
-
Shares change
-
+1.37M
-
Total reported value, excl. options
-
$2.85B
-
Value change
-
+$55.5M
-
Put/Call ratio
-
0.63
-
Number of buys
-
86
-
Number of sells
-
-75
-
Price
-
$41.06
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q2 2024
202 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q2 2024.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.3M shares
.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (7.31M shares), BlackRock Inc. (6.74M shares), BAKER BROS. ADVISORS LP (6.4M shares), RA CAPITAL MANAGEMENT, L.P. (6.08M shares), GOLDMAN SACHS GROUP INC (5.29M shares), PERCEPTIVE ADVISORS LLC (3.45M shares), VANGUARD GROUP INC (3.36M shares), NEA Management Company, LLC (2.91M shares), Frazier Life Sciences Management, L.P. (2.37M shares), and STATE STREET CORP (2M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.